REVIEW PAPER
A possible link between the Epstein-Barr virus infection and autoimmune thyroid disorders
 
More details
Hide details
 
Submission date: 2016-03-13
 
 
Final revision date: 2016-05-25
 
 
Acceptance date: 2016-06-21
 
 
Publication date: 2016-10-25
 
 
Cent Eur J Immunol 2016;41(3):297-301
 
KEYWORDS
ABSTRACT
The Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the Herpesviridae virus family. EBV infection can cause infectious mononucleosis (IM) in the lytic phase of EBV’s life cycle. Past EBV infection is associated with lymphomas, and may also result in certain allergic and autoimmune diseases. Although potential mechanisms of autoimmune diseases have not been clearly elucidated, both genetic and environmental factors, such as infectious agents, are considered to be responsible for their development. In addition, EBV modifies the host immune response. The worldwide prevalence of autoimmune diseases shows how common this pathogen is. Normally, the virus stays in the body and remains dormant throughout life. However, this is not always the case, and a serious EBV-related illness may develop later in life. This explains the chronic course of autoimmune diseases that is often accompanied by exacerbations of symptoms. Based on the present studies, EBV infection can cause autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), Sjögren’s syndrome, and autoimmune hepatitis. The EBV has also been reported in patients with autoimmune thyroid disorders. Although EBV is not the only agent responsible for the development of autoimmune thyroid diseases, it can be considered a contributory factor.
REFERENCES (54)
1.
Bocian J, Januszkiewicz-Lewandowska D (2011): Zakażenia EBV – cykl życiowy, metody diagnostyki, chorobotwórczość. Postepy Hig Med Dosw (Online) 65: 286-298.
 
2.
Piecyk-Sidor M, Polz-Dacewicz MA (2005): Ocular involvement in Epstein-Barr virus infection. Postepy Hig Med Dosw (Online) 59: 602-607.
 
3.
Crawford DH (2001): Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356: 461-473.
 
4.
Miyashita EM, Yang B, Lam KM, et al. (1995): A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80: 593-601.
 
5.
Toussirot E, Roudier J (2008): Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 22: 883-896.
 
6.
Barzilai O, Sherer Y, Ram M, et al. (2007): Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 1108: 567-577.
 
7.
Wucherpfennig KW (2001): Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108: 1097-1104.
 
8.
Lotz M, Roudier J (1989): Epstein-Barr virus and rheumatoid arthritis: cellular and molecular aspects. Rheumatol Int 9: 147-152.
 
9.
Kanegane H, Wakiguchi H, Kanegane C, et al. (1997): Viral interleukin-10 in chronic active Epstein-Barr virus infection.
 
10.
J Infect Dis 176: 254-257.
 
11.
Szmidt A, Stańczyk-Przyłuska A (2005): Rola wirusa EBV w patogenezie chorób alergicznych. Alergia Astma Immmunologia 4: 169-174.
 
12.
Tomer Y, Davies TF (1993): Infection, thyroid disease, and autoimmunity. Endocr Rev 14: 107-120.
 
13.
Kasprzak A, Spachacz R, Wachowiak J, et al. (2007): Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin’s lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules. Folia Histochem Cytobiol 45: 169-179.
 
14.
Evans AS, Rothfield NF, Niederman JC (1971): Raised antibody titres to E.B. virus in systemic lupus erythematosus. Lancet 1: 167-168.
 
15.
James JA, Kaufman KM, Farris AD, et al. (1997): An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100: 3019-3026.
 
16.
Fernández-Menéndez S, Fernández-Morán M, Fernández-Vega I, et al. (2016): Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies. J Neurol Sci 361: 213-219.
 
17.
Ball RJ, Avenell A, Aucott L, et al. (2015): Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis. Arthritis Res Ther 17: 274.
 
18.
Kivity S, Arango MT, Ehrenfeld M, et al. (2014): Infection and autoimmunity in Sjogren’s syndrome: a clinical study and comprehensive review. J Autoimmun 51: 17-22.
 
19.
Fox RI, Pearson G, Vaughan JH (1986): Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjogren’s syndrome. J Immunol 137: 3162-3168.
 
20.
Vento S, Guella L, Mirandola F, et al. (1995): Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 346: 608-609.
 
21.
Tsokos GC, Magrath IT, Balow JE (1983): Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 131: 1797-1801.
 
22.
Toussirot E, Roudier J (2007): Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine 74: 418-426.
 
23.
Fox RI, Luppi M, Pisa P, Kang HI (1992): Potential role of Epstein-Barr virus in Sjogren’s syndrome and rheumatoid arthritis. J Rheumatol Suppl 32: 18-24.
 
24.
Nagata K, Okuno K, Ochi M, et al. (2015): Production of thyrotropin receptor antibodies in acute phase of infectious mononucleosis due to Epstein-Barr virus primary infection: a case report of a child. Springerplus 4: 456.
 
25.
Juszkiewicz A, Tłustochowicz W (2011): Prevalence of anti-thyroid antibodies and thyroid dysfunction in selected rheumatic diseases. Reumatologia 49: 132-137.
 
26.
Janegova A, Janega P, Rychly B, et al. (2015): The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases. Endokrynol Pol 66: 132-136.
 
27.
Tozzoli R, Barzilai O, Ram M, et al. (2008): Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 8: 112-115.
 
28.
Davies TF (2008): Infection and autoimmune thyroid disease. J Clin Endocrinol Metab 93: 674-676.
 
29.
Hansen PS, Brix TH, Iachine I, et al. (2006): The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol 154: 29-38.
 
30.
Brix TH, Christensen K, Holm NV, et al. (1998): A population-based study of Graves’ disease in Danish twins. Clin Endocrinol (Oxf) 48: 397-400.
 
31.
Kondrashova A, Viskari H, Haapala AM, et al. (2008): Serological evidence of thyroid autoimmunity among schoolchildren in two different socioeconomic environments. J Clin Endocrinol Metab 93: 729-734.
 
32.
Misaki T, Iida Y, Kasagi K, Konishi J (2003): Seasonal variation in relapse rate of graves’ disease after thionamide drug treatment. Endocr J 50: 669-672.
 
33.
Harii N, Lewis CJ, Vasko V, et al. (2005): Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto’s autoimmune thyroiditis. Mol Endocrinol 19: 1231-1250.
 
34.
Penhale WJ, Young PR (1988): The influence of the normal microbial flora on the susceptibility of rats to experimental autoimmune thyroiditis. Clin Exp Immunol 72: 288-292.
 
35.
Carter JK, Smith RE (1983): Rapid induction of hypothyroidism by an avian leukosis virus. Infect Immun 40: 795-805.
 
36.
Wolf MW, Misaki T, Bech K, et al. (1991): Immunoglobulins of patients recovering from Yersinia enterocolitica infections exhibit Graves’ disease-like activity in human thyroid membranes. Thyroid 1: 315-320.
 
37.
Wasserman EE, Nelson K, Rose NR, et al. (2009): Infection and thyroid autoimmunity: A seroepidemiologic study of TPOaAb. Autoimmunity 42: 439-446.
 
38.
Kawai H, Inui T, Kashiwagi S, et al. (1992): HTLV-I infection in patients with autoimmune thyroiditis (Hashimoto’s thyroiditis). J Med Virol 38: 138-141.
 
39.
Akamine H, Takasu N, Komiya I, et al. (1996): Association of HTLV-I with autoimmune thyroiditis in patients with adult T-cell leukaemia (ATL) and in HTLV-I carriers. Clin Endocrinol (Oxf) 45: 461-466.
 
40.
Matsuda T, Tomita M, Uchihara JN, et al. (2005): Human T cell leukemia virus type I-infected patients with Hashimoto’s thyroiditis and Graves’ disease. J Clin Endocrinol Metab 90: 5704-5710.
 
41.
Zandman-Goddard G, Shoenfeld Y (2002): HIV and autoimmunity. Autoimmun Rev 1: 329-337.
 
42.
Drabick JJ, Horning VL, Lennox JL, et al. (1991): A retrospective analysis of diseases associated with indeterminate HIV western blot patterns. Mil Med 156: 93-96.
 
43.
Wick G, Grubeck-Loebenstein B, Trieb K, et al. (1992): Human foamy virus antigens in thyroid tissue of Graves’ disease patients. Int Arch Allergy Immunol 99: 153-156.
 
44.
Desailloud R, Hober D (2009): Viruses and thyroiditis: an update. Virol J 6: 5.
 
45.
Thomas D, Liakos V, Michou V, et al. (2008): Detection of herpes virus DNA in post-operative thyroid tissue specimens of patients with autoimmune thyroid disease. Exp Clin Endocrinol Diabetes 116: 35-39.
 
46.
Pender MP (2012): CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis 2012: 189096.
 
47.
Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007): Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
 
48.
Akahori H, Takeshita Y, Saito R, et al. (2010): Graves’ disease associated with infectious mononucleosis due to primary Epstein-Barr virus infection: report of 3 cases. Intern Med 49: 2599-2603.
 
49.
Nagata K, Nakayama Y, Higaki K, et al. (2015): Reactivation of persistent Epstein-Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface. Autoimmunity 48: 328-335.
 
50.
Vrbikova J, Janatkova I, Zamrazil V, et al. (1996): Epstein-Barr virus serology in patients with autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 104: 89-92.
 
51.
Thomas D, Karachaliou F, Kallergi K, et al. (2008): Herpes virus antibodies seroprevalence in children with autoimmune thyroid disease. Endocrine 33: 171-175.
 
52.
Lam KY, Lo CY, Kwong DL, et al. (1999): Malignant lymphoma of the thyroid. A 30-year clinicopathologic experience and an evaluation of the presence of Epstein-Barr virus. Am J Clin Pathol 112: 263-270.
 
53.
Takahashi K, Kashima K, Daa T, et al. (1995): Contribution of Epstein-Barr virus to development of malignant lymphoma of the thyroid. Pathol Int 45: 366-374.
 
54.
Watanabe N, Noh JY, Narimatsu H, et al. (2011): Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto’s disease. Br J Haematol 153: 236-243.
 
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top